Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study

Supportive Care in Cancer

Volumn 24, Issue 10, 2016, Pages 4123-4130

  Wells, Kristen J ^a,b,c   Pan, Tonya M ^b,c   Vázquez Otero, Coralia ^d   Ung, Danielle ^d   Ustjanauskas, Amy E ^b,c   Muñoz, Dariana ^e   Laronga, Christine ^d,f   Roetzheim, Richard G ^d,f   Goldenstein, Marissa ^a   Carrizosa, Claudia ^e   Nuhaily, Sumayah ^g   Johnson, Kenneth ^h   Norton, Marilyn ^h   Sims, Elizabeth ⁱ   Quinn, Gwendolyn P ^d,f  

^a SAN DIEGO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e SAN DIEGO STATE UNIVERSITY   (United States)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^g EMORY UNIVERSITY   (United States)

^h South County Oncology and Hematology   (United States)

ⁱ SHARP HEALTHCARE   (United States)

Author keywords

Breast cancer; Breast neoplasms; Cancer; Medication adherence; Oncology

Indexed keywords

ANASTROZOLE; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER HORMONE THERAPY; CANCER PAIN; CANCER SURVIVOR; CLINICAL ARTICLE; CONSTIPATION; CONTENT ANALYSIS; COUGHING; CROSS-SECTIONAL STUDY; DEPRESSION; DROWSINESS; DRUG COST; FEMALE; HAIR LOSS; HOT FLUSH; HUMAN; MEDICALLY UNDERSERVED; MEDICATION COMPLIANCE; MOOD DISORDER; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITATIVE RESEARCH; SEMI STRUCTURED INTERVIEW; SKIN DISEASE; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; BREAST NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; STATISTICS AND NUMERICAL DATA; SURVIVOR;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; QUALITATIVE RESEARCH; SURVIVORS;

EID: 84966335608     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-016-3229-8     Document Type: Article

References (32)

1. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014
2. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T et al (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62:220–41
3. Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–95
4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer V.2.2010. 2010 [cited 2010 Mar 16]; Available from: http://www.nccn.org
5. Winer EP (2004) American Society of Clinical Oncology Technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23:619–29
6. Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai W-Y et al (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28:4120–8
7. American Cancer Society (2013) Breast cancer facts & figures 2013-2014. Atlanta: American Cancer Society, Inc.
8. Rao RD, Cobleigh MA (2012) Adjuvant endocrine therapy for breast cancer. Oncology 26:541–7
9. Doggrell SA (2011) Adherence to oral endocrine treatments in women with breast cancer: can it be improved? Breast Cancer Res Treat 129:299–308
10. Lash TL, Fox MP, Buist DSM, Wei F, Field TS, Frost FJ et al (2007) Mammography surveillance and mortality in older breast cancer survivors. J Clin Oncol 25:3001–6
11. Abe O, Abe R, Enomoto KT, Kikuchi K, Koyama H, Nomura Y et al (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451–67
12. Schiavon G, Smith IE (2014) Status of adjuvant endocrine therapy for breast cancer. Breast Cancer Res 16:206
13. Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134:459–78
14. Huiart L, Ferdynus C, Giorgi R (2013) A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians. Breast Cancer Res Treat 138:325–8
15. Reynolds KL, Higgins MJ (2013) Endocrine therapy for breast cancer: a tough pill to swallow. Menopause 20:714–6
16. Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S et al (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30:936–42
17. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE et al (2010) American Society of Clinical Oncology Clinical Practice Guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784–96
18. Simon R, Latreille J, Matte C, Desjardins P, Bergeron E (2014) Adherence to adjuvant endocrine therapy in estrogen receptor–positive breast cancer patients with regular follow-up. Can J Surg 57:26–32
19. Hadji P (2010) Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 73:156–66
20. Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99:215–20
21. Van Liew JR, Christensen AJ, de Moor JS (2014) Psychosocial factors in adjuvant hormone therapy for breast cancer: an emerging context for adherence research. J Cancer Surviv 8(3):521–31. doi:10.1007/s11764-014-0374-2
22. Pellegrini I, Sarradon-Eck A, Ben Soussan P, Lacour A-C, Largillier R, Tallet A et al (2010) Women’s perceptions and experience of adjuvant tamoxifen therapy account for their adherence: breast cancer patients’ point of view. Psychooncology 19:472–9
23. Harrow A, Dryden R, McCowan C, Radley A, Parsons M, Thompson AM et al (2014) A hard pill to swallow: a qualitative study of women’s experiences of adjuvant endocrine therapy for breast cancer. BMJ Open 4, e005285
24. Warnecke RB, Oh A, Breen N, Gehlert S, Paskett E, Tucker KL et al (2008) Approaching health disparities from a population perspective: The National Institutes of Health Centers for Population Health and Health Disparities. Am J Public Health 98:1608–15
25. Patton M. Qualitative Research and Evaluation Methods (2002) Sage Publications, London
26. ATLAS.ti [Internet]. Berlin: Scientific Software Development GmbH; 2010. Available from: http://www.atlasti.com/index.html
27. Knodel J (1993) The design and analysis of focus group studies: a practical approach. Success. Focus Groups Adv. State Art. London: Sage Publications. p. 35–50
28. Borg W, Gall M (1989) Educational research: an introduction. Longman, New York
29. Krueger R (1998) Moderating Focus Groups. Sage Publications, Thousand Oaks
30. IBM SPSS Statistics Version 20. IBM Corporation, 2011.
31. Zullig LL, Peterson ED, Bosworth HB (2013) Ingredients of successful interventions to improve medication adherence. JAMA 310:2611–2
32. The Cochrane Collaboration, editor. Cochrane Database of Systematic Reviews: Protocols [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 1996 [cited 2014 Jul 28]. Available from: http://doi.wiley.com/10.1002/14651858